-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 8, Tianjing Bio announced that the US Phase 1 clinical study of the new drug Protollin for the treatment of Alzheimer's disease has completed the first patient administration
Today, there are approximately tens of millions of Alzheimer's patients worldwide and there is no effective cure
According to the previous cooperation agreement, Tianjing Biotechnology and Jiangsu Enhua Pharmaceutical obtained the global development, production and commercialization of Protollin from the Brigham Hospital affiliated to Harvard Medical School and Inspirevax (formerly known as "Biodextris")
Note: The original text has been deleted